Table 3. Association of stromal histological features with classical prognostic markers, metastatic recurrence and local relapse of 56 untreated early breast cancer patients.
| Characteristics | n | Intra-tumor stroma | Fibroblasts | Collagen deposition | Lymphocytic infiltration | Myxoid changes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| > 50 | p (adjusted p) * | Large amount | p (adjusted p) * | Large amount | p (adjusted p) * | Large amount | p (adjusted p) * | Large amount | p (adjusted p) * | ||
| Age (years) | |||||||||||
| < 50 | 8 | 4 (50.00) | >0.9999 | 4 (50.00) | >0.9999 | 4 (50.00) | 0.1868 | 1 (12.50) | 0.6887 | 8 (100.00) | 0.1767 |
| ≥ 50 | 40 | 22 (55.00) | (>0.9999) | 18 (45.00) | (>0.9999) | 31 (77.50) | (0.8739) | 8 (20.00) | (0.9598) | 30 (75.00) | (0.8573) |
| Tumor size (cm) | |||||||||||
| <2 | 37 | 25 (67.57) | 0.0045 | 20 (54.05) | 0.3487 | 28 (75.68) | >0.9999 | 4 (10.81) | 0.0519 | 27 (72.97) | 0.0450 |
| ≥ 2 | 14 | 3 (21.43) | (0.0737) | 5 (35.71) | (0.8381) | 10 (71.43) | (>0.9999) | 5 (35.71) | (0.4533) | 14 (100.00) | (0.4211) |
| Histological grade | |||||||||||
| G1/G2 | 28 | 20 (71.43) | 0.0120 | 13 (46.43) | 0.7812 | 21 (75.00) | >0.9999 | 3 (10.71) | 0.2682 | 18 (64.28) | 0.0011 |
| G3 | 23 | 8 (34.78) | (0.1747) | 12 (52.17) | (0.9654) | 17 (73.91) | (>0.9999) | 6 (26.09) | (0.8569) | 23 (100.00) | (0.0240) |
| HER2/neu status | |||||||||||
| Negative | 30 | 17 (56.67) | 0.7828 | 16 (53.33) | 0.5725 | 21 (70.00) | 0.5180 | 4 (13.33) | 0.4601 | 22 (73.33) | 0.1666 |
| Positive | 21 | 11 (52.38) | (0.9495) | 9 (42.86) | (0.8928) | 17 (80.95) | (0.9425) | 5 (23.81) | (0.9273) | 19 (90.48) | (0.9093) |
| ER status | |||||||||||
| Negative | 14 | 9 (64.29) | 0.5327 | 5 (35.71) | 0.3487 | 9 (64.29) | 0.4723 | 4 (28.57) | 0.2362 | 11 (78.57) | >0.9999 |
| Positive | 37 | 19 (51.35) | (0.9182) | 20 (54.05) | (0.8381) | 29 (78.38) | (0.9374) | 5 (13.51) | (0.8595) | 30 (81.08) | (>0.9999) |
| PR status | |||||||||||
| Negative | 13 | 7 (53.85) | >0.9999 | 5 (38.46) | 0.5230 | 8 (61.54) | 0.2743 | 3 (23.08) | 0.6764 | 10 (76.92) | >0.9999 |
| Positive | 38 | 21 (55.26) | (>0.9999) | 20 (52.63) | (0.9135) | 30 (78.95) | (0.8356) | 6 (15.79) | (0.9528) | 31 (81.58) | (>0.9999) |
| Regional lymph nodes | |||||||||||
| Negative | 37 | 22 (59.46) | 0.5204 | 18 (48.65) | >0.9999 | 28 (75.68) | 0.7193 | 7 (18.92) | >0.9999 | 29 (78.38) | 0.7134 |
| Positive | 13 | 6 (46.15) | (0.9337) | 6 (46.15) | (>0.9999) | 9 (69.23) | (0.9423) | 2 (15.38) | (>0.9999) | 11 (84.62) | (0.9536) |
| Metastatic recurrence | |||||||||||
| Negative | 36 | 19 (52.78) | 0.7310 | 20 (55.56) | 0.3177 | 25 (69.44) | 0.2440 | 6 (16.67) | 0.6631 | 28 (77.78) | >0.9999 |
| Positive | 11 | 7 (63.64) | (0.9481) | 4 (36.36) | (0.8324) | 10 (90.91) | (0.8196) | 3 (27.27) | (0.9442) | 9 (81.82) | (>0.9999) |
| Local relapse | |||||||||||
| Negative | 42 | 22 (52.38) | 0.3623 | 23 (54.76) | 0.1882 | 31 (73.81) | >0.9999 | 7 (16.67) | 0.2397 | 34 (80.95) | 0.5694 |
| Positive | 5 | 4 (80.00) | (0.8475) | 1 (20.00) | (0.8501) | 4 (80.00) | (>0.9999) | 2 (40.00) | (0.8263) | 3 (60.00) | (0.8987) |
HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor.
*The association between variables was performed using the Fisher Exact-test. Multiple testing adjusted p-values were computed using the Benjamini-Hochberg correction